Top 30 pharma company running a large open-label extension study for a CNS indication and the sole reason for keeping the trial in place was to ensure trial patients benefiting from treatment could continue to gain access. It was expected that commercial launch would not take place for 3-4 years in some countries.

Read the case study to find out how Clinigen ensured patients were not negatively impacted by the closure of the trial.